Skip to main content
MGRX
NASDAQ Industrial Applications And Services

Mangoceuticals Sets Series D Terms: $15 Liquidation Preference, 8% Cash Dividends, 3-Year Conversion Lock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.155
Mkt Cap
$3.445M
52W Low
$0.15
52W High
$2.28
52W Position info
3.7% above low
Off High info
93% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

MGRX is trading near its 52-week low of $0.15 (3.7% above the low).

Summary

Mangoceuticals disclosed the full terms of its planned 8% Series D convertible preferred: $10 stated value, $15 liquidation preference, cash-only 8% dividends stepping to 10% on default, and no conversion for three years. Existing preferred holders waived their protective provisions to let the senior series rank ahead of them.


Key Events · Financing and Capital Events · MGRX

  • Series D Terms Finalized

    A Certificate of Designations effective November 9, 2026 establishes 1,000,000 shares of 8% Series D convertible preferred with a $10.00 stated value and a $15.00 per-share liquidation preference.

  • Cash Dividend Burden

    Dividends accrue at $0.80 per share per year, payable solely in cash quarterly, and step up to 10% per annum during any payment default — roughly $800K a year if all 1,000,000 shares are sold.

  • Conversion Price Not Yet Set

    The conversion price equals three times the 10-day VWAP before Form 1-A qualification, floored at 20% of the Nasdaq Minimum Price, and conversion is barred until the third anniversary of issuance plus any required stockholder approval.

  • Existing Preferred Waived Protections

    Amendments to the Series B and Series C waive variable-rate transaction and repurchase restrictions and subordinate both classes to the new Series D in dividends and liquidation.


Analysis · MGRX · Industrial Applications And Services

The economics of the 8% Series D convertible preferred Mangoceuticals plans to sell under Regulation A are now spelled out, and for a company this small the capital is expensive. Each $10.00 share accrues $0.80 a year in cash-only dividends and ranks ahead of the common, Series B and Series C in liquidation at $15.00 per share — a 150% preference. Holders cannot convert for three years, and the conversion price will be set at three times the 10-day VWAP before the Form 1-A is qualified, so the eventual share count depends on where the stock trades at that moment. Against a $0.155 stock price, a 3x-VWAP formula implies a conversion price far above today's level, which limits near-term dilution but also makes the paper unattractive to convert — leaving the cash dividend as the real cost. To let this happen, Series B and Series C holders waived their variable-rate and repurchase protections, subordinating their claims and removing guardrails that previously limited new senior paper. With cash of $229K as of the last 10-Q, a going-concern warning and a pending reverse-split proxy to cure the Nasdaq bid-price deficiency, this is survival financing priced accordingly.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MGRX was trading at $0.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $0.15 to $2.28. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MGRX - Latest Insights

MGRX
Nov 12, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.2078
Real-time Price: $0.155 info
Change: -$0.0528 (-25%) info
Market Cap: $3.445M info
MGRX
Nov 06, 2026, 5:25 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.190
Real-time Price: $0.155 info
Change: -$0.035 (-18%) info
Market Cap: $3.445M info
MGRX
Nov 06, 2026, 5:25 PM EST
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.190
Real-time Price: $0.155 info
Change: -$0.035 (-18%) info
Market Cap: $3.445M info
MGRX
Oct 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.430
Real-time Price: $0.155 info
Change: -$0.275 (-64%) info
Market Cap: $3.445M info
MGRX
Oct 09, 2026, 4:00 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $0.4251
Real-time Price: $0.155 info
Change: -$0.2701 (-64%) info
Market Cap: $3.445M info